F 0758
Level of Harm - Actual harm
Residents Affected - Few
Implement gradual dose reductions(GDR) and non-pharmacological interventions, unless contraindicated,
prior to initiating or instead of continuing psychotropic medication; and PRN orders for psychotropic
medications are only used when the medication is necessary and PRN use is limited.
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
interview and record review, the facility failed to monitor for behaviors and report the side effects of a
resident's anti-psychotic medication. This failure resulted in R4 continuing to receive Seroquel and
experiencing a hospitalization, increased falls, and inability to participate in his rehab care.
This applies to 1 out of 3 (R4) residents reviewed for psychotropics.
The findings include:
R4's EMR (Electronic Medical Record) showed R4 was admitted to the facility on [DATE] with multiple
diagnoses including a history of falls, metabolic encephalopathy, vascular dementia, depression, epilepsy,
convulsions, hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side,
urinary tract infections, and left femur fracture. R4's MDS (Minimum Data Set) dated 10/18/2024 showed he
was severely cognitively impaired and receiving high-risk medications including antipsychotics,
antidepressants, and anticonvulsants. R4's EMR showed he was transferred to the hospital on [DATE] and
did not return to the facility.
On 12/31/2024 at 8:50 AM, V8 (R4's Wife) said she would visit R4 frequently at the facility and became
worried because he started to become overly sedated as if drugged and having multiple falls.
On 1/2/2025 at 9:00 AM, V14 (Registered Nurse/RN) said she had been R4's routine morning nurse during
his stay at the facility. V14 said R4 was nice but would become agitated when his wife was not present. V14
said R4 was a high risk for falls and had to be redirected frequently. V14 said R4 was hospitalized because
he was noted to be too sleepy. V14 said R4 was non-decisional and V8 (R4's Wife) was his representative
and decision-maker.
On 1/2/2025 at 10:20 AM, V12 (Geriatric Nurse Practitioner/NP) said she had assisted in managing R4's
primary care at the facility. V12 said she did not prescribe R4's Seroquel medication but had decreased,
held, and discontinued it because she was informed he was too sedated. V12 said R4's behavior was
difficult to manage and difficult to find the right balance of treatment. V12 said ultimately V13 (R4's
Psychiatric NP) should have been notified as the ordering prescriber for Seroquel.
On 1/2/2025 at 11:00 AM, V13 (Psychiatric NP) said she was consulted to treat R4 for behavior of agitation
related to his dementia and managing his Seroquel. V13 said she last saw R4 on 11/7/2024 and decreased
his Seroquel after she was informed of his fall. V13 said the facility should have called her first to inform her
of R4's side effects as practice for managing residents receiving
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 4
Event ID:
145689
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145689
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
01/02/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Pearl of Elk Grove, The
1920 Nerge Road
Elk Grove Village, IL 60007
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0758
Level of Harm - Actual harm
Residents Affected - Few
psychotropics. V13 said R4 had a lot of adjustments in a short period of time, which made it harder to
identify the right dose for him. V13 said this could have contributed to R4 becoming more unstable and
lethargic. V13 said it was always better to be cautious when using antipsychotics and that's why she started
to taper his Seroquel in November. V13 said she did not contact R4's wife but discussed her
recommendations with the facility's nurses. V13 said R4 was showing signs of sundowning (increased
confusion in the evening hours) and would have also benefited from nonpharmacological approaches such
as sleep hygiene promotion practices, activities, and family visits in the evenings.
R4's comprehensive care plan showed R4 had a focus problem for the use of Seroquel (antipsychotic)
medication for Alzheimer's disease initiated and last updated on 6/6/2024. The focus problem included a
goal for R4 to reduce the use of psychotropic medications and included the interventions of Monitor for side
effects and effectiveness [every] SHIFT. Consult with pharmacy, MD to consider dosage reduction when
clinically appropriate at least quarterly. R4's care plan did not show any resident-centered target behaviors
or non-pharmacological approaches for the use of Seroquel.
R4's Order Summary Report dated 1/2/2025 showed R4 was started on SEROquel Oral Tablet 25 MG
[milligrams] Give 1 tablet by mouth two times a day for depression on 6/6/2024. R4's EMAR (Electronic
Medication Administration Record) showed R4 received Seroquel 25 mg twice a day until 9/10/2024.
The Report showed R4 was started on an additional dose of SEROquel Oral Tablet 25 MG Give 1 tablet by
mouth at bedtime related to UNSPECIFIED DEMENTIA on 6/13/2024. R4's EMAR showed R4 received
Seroquel 25 mg at bedtime as well until 8/14/2024.
R4's Order Summary Report showed R4 was started on an additional as needed dose of SEROquel Oral
Tablet 25 MG by mouth every 24 hours as needed for Behavioral disturbances on 7/29/2024. R4's EMAR
showed R4 had the order active for Seroquel PRN (as needed) until 10/15/2024 (79 days). The EMAR
showed R4 received Seroquel PRN on 8/1/2024, 8/14/2024, and 8/23/2024.
R4's Order Summary Report then showed R4's Seroquel at bedtime was increased to 75 mg on 8/15/2024
with the order SEROquel Oral Tablet 25 MG give 3 tablet by mouth at bedtime related to UNSPECIFIED
DEMENTIA.
R4's Progress Note dated 9/11/2024 said, Informed [V12 (Geriatric Nurse Practitioner/NP)] patient is
sleeping most of the time in the morning after breakfast fall asleep again .D/C Seroquel during the day and
leave Seroquel at bedtime, hold if sedated. V13's Psychiatric Periodic Evaluation note dated 9/12/2024
said, Nursing staff reported that dosage of Seroquel during the day was discontinued due to excessive
daytime sedation. The evaluation said R4 was to continue with Seroquel 25 mg every 24hrs PRN, Seroquel
75 mg at bedtime for agitation/Psychosis, and to monitor for changes in mood and behaviors.
R4's Pharmacy Recommendation dated 9/16/2024 said there were recommendations for a GDR (gradual
dose reduction) for SEROQUEL 75MG QHS and a need for stop date of 14 days for PRN order for
Seroquel. The recommendation was declined by V13 (Psychiatric NP) because the Patient has had good
response to treatment and requires this dose for condition stability.
R4's EMAR showed R4 received Seroquel 75 mg at bedtime until 9/17/2024. R4's Progress Note dated
9/18/2024 said, Informed [V12 (Geriatric NP)] that patient during the day there are times that patient is just
sleeping, doesn't want to participate in the therapy .order reduce seroquel 50mg at bedtime.
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145689
If continuation sheet
Page 2 of 4
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145689
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
01/02/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Pearl of Elk Grove, The
1920 Nerge Road
Elk Grove Village, IL 60007
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0758
Level of Harm - Actual harm
Residents Affected - Few
V13's Psychiatric Periodic Evaluation note dated 9/19/2024 said, The patient was referred to us today due
to worsening depression and a lack of motivation. According to nursing staff, the patient has displayed little
motivation lately, dragging himself around and showing a disinterest in participating in any activities,
indicating worsening depression. The patient was seen sitting around the nursing station, confused at
baseline, and was unresponsive during our interaction. Nursing staff recently discontinued his daytime dose
of Seroquel, and while the patient is now more alert, he suntil does not engage much which is unusual for
him. The evaluation said R4 was started on another psychotropic medication of Bupropion 100mg daily
(antidepressant).
R4's NP Progress Note from V12 (Geriatric NP) dated 9/20/2024 said, Pt seen for somnolence HPI Pt has
been more sleepy. Seroquel reduced. V13's Psychiatric Periodic Evaluation note dated 10/3/2024 said
Declined GDR recommendation for Seroquel at bedtime due to risk for decompensation.
R4's Progress Note dated 10/14/2024 said, Resident slipped and fell from wheelchair hitting his head on
the floor. Resident sustained a cut on his right forehead .Dr on file was reached and ordered resident to be
sent out to ER. R4's Progress Note dated 10/15/2024 said, Pt is admitted for altered mental status.
R4's Order Summary Report showed R4 was restarted on 50 mg at bedtime on 10/17/2024 with the order
SEROquel Oral Tablet 25 MG Give 2 tablet by mouth at bedtime for bipolar disorder. The Report then
showed on 10/26/2024, R4 was started on SEROquel Oral Tablet 25 MG Give 1 tablet by mouth two times
a day for behavioral disturbances. R4's Progress Note dated 10/17/2024 said, Upon admission, res
appeared very sleepy not verbally responsive even with much verbal cuing from staff and paramedics. His
eyelids were quivering and throat had visible swallowing reflex. After about 10 minutes with verbal prodding
from staff to say something res said hello and opened his eyes.
R4's Progress Note dated 10/26/2024 said, Called [V13 (Psychiatric NP)] for patient being restless and
keep on standing. Patient is very unsteady to stand up. NP ordered for Seroquel 25mg bid. Informed wife.
R4's Progress Note dated 10/27/2024 said, Change in Condition/s reported this CIC Evaluation are/were:
Altered mental status .Altered level of consciousness (hyperalert, drowsy but easily aroused, difficult to
arouse) Functional Status Evaluation: General weakness .Primary Care Provider responded with the
following feedback .Monitor him closely.
R4's Progress Note dated 11/2/2024 said SEROquel Oral Tablet 25 MG Give 1 tablet by mouth two times a
day for behavioral disturbances patient appears calm and relaxed poa stated not to give.
R4's Progress Note dated 11/7/2024 said, Seen by [V13 (Psychiatric NP)] due to sleepy during the day. D/C
seroquel on 9am dose.
R4's EMAR showed R4 received Seroquel 25 mg twice a day until 11/7/2024, and received Seroquel 50 mg
at bedtime until 11/9/2024. R4's Progress Note dated 11/10/2024 said R4 fell and was transferred to the
hospital for an evaluation.
R4's EMARs from August through November 2024 showed an order for monitoring the use of
Anti-Psychotic Medication Use: Observe closely for significant side effects, sedation, drowsiness, dry
mouth, constipation, blurred vision, extra pyramidal reaction, weight gain, edema, postural hypotension,
sweating, loss of appetite, urinary retention. Enter the number of times side effect noted. (Requires
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145689
If continuation sheet
Page 3 of 4
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145689
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
01/02/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Pearl of Elk Grove, The
1920 Nerge Road
Elk Grove Village, IL 60007
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0758
progress note of physician notification for each occurrence) every shift for Monitoring. R4's EMARs showed
no side effects were documented for R4.
Level of Harm - Actual harm
Residents Affected - Few
R4's EMARs from August through November 2024 showed an order for Monitor/Record if targeted behavior
of Agitation occurs every shift for Monitoring indicate if behavior occurred by indication the number of times
observed. R4's EMARs showed R4 had the behavior documented on 11/8/2024 and 11/9/2024.
R4's Incidents By Incident Type fall report dated 1/2/2025 said R4 had a total of 20 fall incidents during his
stay at the facility. The report showed R4's initial fall was on 6/9/2024 (after starting Seroquel). The report
showed R4 also fell on 6/11/2024, 6/14/2024, 6/28/2024, 7/2/2024, 7/6/2024, 7/23/2024, 8/2/2024,
8/19/2024, 8/26/2024, 8/31/2024, 10/5/2024, 10/7/2024, 10/10/2024, 10/11/2024, 10/14/2024, 10/27/2024,
11/2/2024, 11/5/2024, 11/8/2024, and 11/10/2024.
V16's (R4's Neurologist) Progress Notes dated 8/29/2024, 9/24/2023, and 10/31/2024 said [reccommend]
limit seroquel.
The facility's policy titled Psychotropic Drug Use dated 6/11/2024 said, The purpose is to promote the safe
and effective use of psychotropic medications that are used in lowest possible dose and time frame and
have indication for the use that enhances the resident's quality of life .Initiating the Use of Psychotropic
Medications .4. Every attempt will be made to utilize the lowest possible dose of the medication .7. If an
order is obtained for a Psychotropic Medication, the resident, family or POA must be informed of the risks
and benefits of the medication The care plan will be developed with input from the resident, family, legal
representative and include participation from the IDT (Interdisciplinary Team). 3. The care plan will be
developed initially upon the start of the medication and be reviewed at least quarterly or more often as the
resident's condition dictates .Monitoring and Gradual Dose Reduction .The Psychiatrist/PCP will review the
continued need for the medication and monitor for side effects .The Psychiatrist or ANP will also be notified
and review changes in the resident's condition and behavior or any side of the medications.
The facility's policy titled Behavior and Psychoactive Management Program dated 10/22/2024 said, It is the
policy of the facility to provide care and services to promote our resident's quality of life. It is the philosophy
of the facility that all resident behavior has meaning. Our facility will work diligently to minimize the use of
psychoactive medications in its resident population .a. Program will ensure that staff are monitoring
residents' behavior to establish patterns, determine intensity and frequency behavior is exhibited, and
identify specific targeted behavior/s that can be distressing to the resident. b. The program will assess the
need for psychoactive medication use. Care plans with residents and or resident's representatives will be
scheduled as necessary via phone or in person to discuss behaviors, psychoactive drug order/s and
treatment, and recommended plan of care .e. Evaluating the effectiveness of pharmacological and
non-pharmacological interventions will be performed. f. Monitoring for any adverse side effects of
medications .g. Care plan on focus problem will be developed with approaches to address and manage
identified behaviors .Tapering and Gradual Dose Reduction a. Facility will attempt to achieve the lowest
effective dose, to discontinue the medications that no longer benefit the resident, and to minimize exposer
to increased risk of adverse consequences .iii. Daily behavior monitoring. iv. May schedule resident and
family meetings as necessary.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145689
If continuation sheet
Page 4 of 4